Mankind Pharma , a leading pharmaceutical company, is set to release its financial results for the April-June quarter. According to Bloomberg estimates, the company is expected to report a significant increase in revenue, while net profit may see a decline compared to the same period last year.

Revenue Projections

The consolidated revenue for the quarter is estimated to reach Rs 3,605.53 crore, marking a substantial increase from Rs 2,893.42 crore reported in the corresponding quarter of the previous year. This growth is primarily attributed to the recent acquisition of Bharat Serum Vaccine (BSV).

Bharat Serum Vaccine Contribution

The BSV acquisition is expected to play a crucial role in Mankind Pharma's revenue growth. Analysts project that BSV will contribute approximately Rs 470.00 crore to the company's top line in the quarter.

Profitability and Margins

Despite the anticipated revenue growth, Bloomberg estimates suggest that the net profit may decline to Rs 446.71 crore, compared to Rs 536.49 crore in the same quarter last year. However, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is projected to improve to Rs 900.11 crore from Rs 681.76 crore year-on-year.

The EBITDA margin is expected to expand to 25.00% from 23.60% in the previous year, indicating improved operational efficiency.

Analyst Perspectives

IIFL Capital maintains a positive outlook on Mankind Pharma, with a "Buy" rating and a target price of Rs 2,750. The brokerage firm anticipates a 10% organic growth for the company, excluding the impact of the BSV acquisition.

Axis Capital projects a 24% year-on-year growth in consolidated sales. They expect the EBITDA margins to reach 24.50%. The brokerage also estimates that Mankind Pharma's India business will grow by 8% on an ex-BSV basis.

Financial Performance Overview

As Mankind Pharma prepares to announce its quarterly results, investors and analysts will be closely watching the impact of the BSV acquisition on the company's overall performance and its ability to maintain profitability amidst expansion.

Mankind Pharma , a prominent Indian pharmaceutical company, has taken a significant step in its international expansion strategy by establishing a fully owned subsidiary in Sri Lanka. This move marks the company's direct entry into the Sri Lankan market, potentially strengthening its presence in the South Asian region.

Key Highlights

• Mankind Pharma has incorporated a wholly owned subsidiary in Sri Lanka.
• The new entity is named Mankind Pharma Lanka (Private) Limited.
• The subsidiary was officially incorporated on July 23, 2025.

Strategic Expansion

The establishment of Mankind Pharma Lanka (Private) Limited represents a strategic move by the company to directly enter the Sri Lankan pharmaceutical market. This expansion could potentially allow Mankind Pharma to:

• Gain direct access to Sri Lankan consumers
• Tailor its product offerings to local market needs
• Enhance its distribution capabilities in the region
• Potentially manufacture locally in the future

Corporate Disclosure

In compliance with regulatory requirements, Mankind Pharma has made the necessary disclosures to the stock exchanges. The company informed the BSE Limited and the National Stock Exchange of India Limited about the incorporation of its wholly owned subsidiary in Sri Lanka.

Looking Ahead

While specific details about the operations and immediate plans for the Sri Lankan subsidiary have not been disclosed, this move signals Mankind Pharma's commitment to growth and expansion in international markets. The company's stakeholders will likely be watching closely to see how this new venture contributes to Mankind Pharma's overall business strategy and financial performance in the coming years.

As the pharmaceutical landscape continues to evolve globally, Mankind Pharma's expansion into Sri Lanka could potentially open up new opportunities for the company in the South Asian market.